Study reveals English proficiency, income, and area-level unemployment are among the influential factors and highlights need for tailored interventions to increase screening rates.
How Boehringer Ingelheim and Pfizer battled over the exclusivity of the first Humira interchangeable
Ten companies are now competing for market share with AbbVie’s megablockbuster rheumatoid arthritis drug Humira (adalimumab), but two of those competitors — Pfizer and Boehringer